Custom Zinc-Finger Nucleases for Use in Human Cells

Slides:



Advertisements
Similar presentations
Volume 12, Issue 5, Pages (November 2005)
Advertisements

Volume 10, Issue 2, Pages (August 2004)
Volume 24, Issue 3, Pages (March 2016)
Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia by Hironori.
Mark M Metzstein, H.Robert Horvitz  Molecular Cell 
Volume 11, Issue 6, Pages (June 2003)
A Novel Cofactor for p300 that Regulates the p53 Response
Molecular Therapy - Nucleic Acids
Regulation of Mast Cell Survival by IgE
The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation  Rixun Fang, Nilda A. Santiago, Lynne C. Olds,
High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia by.
Construction of tumor-specific toxins using ubiquitin fusion technique
Brca1 Controls Homology-Directed DNA Repair
Volume 10, Issue 1, Pages (July 2004)
Volume 14, Issue 4, Pages (October 2006)
ROG, Repressor of GATA, Regulates the Expression of Cytokine Genes
Transient Gene Expression by Nonintegrating Lentiviral Vectors
IFN-γ Upregulates Expression of the Mouse Complement C1rA Gene in Keratinocytes via IFN-Regulatory Factor-1  Sung June Byun, Ik-Soo Jeon, Hyangkyu Lee,
Volume 16, Issue 6, Pages (December 2004)
Volume 11, Issue 4, Pages (April 2005)
Volume 2, Issue 4, Pages (October 2000)
Volume 2, Issue 3, Pages (September 1998)
Volume 17, Issue 3, Pages (February 2005)
Volume 114, Issue 6, Pages (June 1998)
Peroxisome Proliferator-Activated Receptor-α Is a Functional Target of p63 in Adult Human Keratinocytes  Silvia Pozzi, Michael Boergesen, Satrajit Sinha,
Volume 17, Issue 3, Pages (February 2005)
Volume 13, Issue 11, Pages (December 2015)
M.Brandon Parrott, Michael A. Barry  Molecular Therapy 
Volume 10, Issue 2, Pages (August 2004)
Yin-Yang 1 Negatively Regulates the Differentiation-Specific Transcription of Mouse Loricrin Gene in Undifferentiated Keratinocytes  Xuezhu Xu, Yasuhiro.
SUMO Promotes HDAC-Mediated Transcriptional Repression
Role of p38 MAPK in Transforming Growth Factor β Stimulation of Collagen Production by Scleroderma and Healthy Dermal Fibroblasts  Madoka Sato, Daniel.
Volume 25, Issue 3, Pages (February 2007)
Volume 14, Issue 6, Pages (February 2016)
Molecular Therapy - Nucleic Acids
Regulation of Mast Cell Survival by IgE
Mutations in Human ARF Exon 2 Disrupt Its Nucleolar Localization and Impair Its Ability to Block Nuclear Export of MDM2 and p53  Yanping Zhang, Yue Xiong 
Transactivator and Structurally Optimized Inducible Lentiviral Vectors
Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor  Dai Iwakiri, Daniel K. Podolsky 
Linking the Rb and Polycomb Pathways
Volume 16, Issue 24, Pages (December 2006)
Volume 8, Issue 1, Pages (July 2003)
17β-estradiol Inhibits the Production of RANTES in Human Keratinocytes
Receptor-Targeted Gene Delivery Using Multivalent Phagemid Particles
ROG, Repressor of GATA, Regulates the Expression of Cytokine Genes
Olivier Humbert, Nancy Maizels  Molecular Therapy - Nucleic Acids 
A CRISPR Approach to Gene Targeting
The p73 Gene Is an Anti-Tumoral Target of the RARβ/γ-Selective Retinoid Tazarotene  Marina Papoutsaki, Mauro Lanza, Barbara Marinari, Steven Nisticò, Francesca.
Inclusion of jaagsiekte sheep retrovirus proviral elements markedly increases lentivirus vector pseudotyping efficiency  Patrick L. Sinn, Erin R. Burnight,
Both Natural and Designed Micro RNAs Can Inhibit the Expression of Cognate mRNAs When Expressed in Human Cells  Yan Zeng, Eric J Wagner, Bryan R Cullen 
Volume 10, Issue 4, Pages (October 2004)
RNA Polymerase II Activity of Type 3 Pol III Promoters
PiggyBac Transposon-mediated Gene Transfer in Human Cells
Yap1 Phosphorylation by c-Abl Is a Critical Step in Selective Activation of Proapoptotic Genes in Response to DNA Damage  Dan Levy, Yaarit Adamovich,
Nuclear Localization and Transcriptional Repression Are Confined to Separable Domains in the Circadian Protein CRYPTOCHROME  Haisun Zhu, Francesca Conte,
Volume 9, Issue 2, Pages (February 2011)
Shrestha Ghosh, Baohua Liu, Yi Wang, Quan Hao, Zhongjun Zhou 
Volume 10, Issue 2, Pages (August 2004)
Defining the Regulatory Elements in the Proximal Promoter of ΔNp63 in Keratinocytes: Potential Roles for Sp1/Sp3, NF-Y, and p63  Rose-Anne Romano, Barbara.
Volume 10, Issue 6, Pages (December 2004)
Jia Liu, Thomas Gaj, Mark C Wallen, Carlos F Barbas 
Endogenous GATA Factors Bind the Core Sequence of the tetO and Influence Gene Regulation with the Tetracycline System  David J. Gould, Yuti Chernajovsky 
Volume 22, Issue 2, Pages (February 2014)
Molecular Therapy - Methods & Clinical Development
Volume 26, Issue 10, Pages (October 2018)
Zinc-Finger Nucleases Induced by HIV-1 Tat Excise HIV-1 from the Host Genome in Infected and Latently Infected Cells  Haiyan Ji, Panpan Lu, Baochi Liu,
Molecular Therapy - Nucleic Acids
Nuclear Localization and Transcriptional Repression Are Confined to Separable Domains in the Circadian Protein CRYPTOCHROME  Haisun Zhu, Francesca Conte,
A Smad Transcriptional Corepressor
Molecular Therapy - Nucleic Acids
Presentation transcript:

Custom Zinc-Finger Nucleases for Use in Human Cells Stephen Alwin, Maja B. Gere, Eva Guhl, Karin Effertz, Carlos F. Barbas, David J. Segal, Matthew D. Weitzman, Toni Cathomen  Molecular Therapy  Volume 12, Issue 4, Pages 610-617 (October 2005) DOI: 10.1016/j.ymthe.2005.06.094 Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Analysis of DNA binding. (A) Sequence motifs. The sequences of the crucial residues of the zinc-finger modules and the corresponding DNA-binding sites are shown. Module “A” was designed to recognize DNA triplet “a” and so on. (B) Schematic. Custom transcription factors (TFs) consist of an HA tag (black box), the VP16 transcriptional activation domain (AD), the SV40 NLS (n), and three zinc-finger modules. The reporter plasmids contain the luciferase gene, a minimal promoter element, and upstream binding sites for the custom TFs (xx). Each x represents a 9-bp recognition motif as defined in (A). (C) Reporter assay. 293T cells were transfected with expression plasmids for the custom TFs and reporter plasmids containing binding sites for GZF1 and GZF2 (1-2/Luc) or GZF3 and GZF4 (3-4/Luc). The graph displays luciferase activity normalized for transfection efficiency and relative to transfection with empty vector (AD). **Statistically significant (P < 0.01). (D) Western blot. Transfected 293T cells were harvested after 40 h and cell lysates probed with an anti-HA antibody. AD-ZF5C is a control zinc-finger protein, while “cto” marks a negative control. Molecular Therapy 2005 12, 610-617DOI: (10.1016/j.ymthe.2005.06.094) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 2 Design and expression kinetics. (A) Design. All ZFNs contain an HA tag (black box), three zinc-finger modules, and the nuclease domain of FokI (Fok1-N). GZF3n-N contains a 21-amino-acid linker, while GZF3-N and nGZF3-N contain a short AAARA linker between the zinc-finger modules and the Fok1-N domain. “P” stands for promoter CMV, PGK, or HSV-tk. (B) Western blot. Transfected 293T cells were harvested after 24 and 48 h and cell lysates probed with an anti-HA antibody. “cto” indicates transfection with empty vector. (C) Apoptosis. The sub-G1 population of transfected 293T cells was determined by flow cytometry of PI-stained cells after 48 h and is shown as the fraction of transfected cells. **Statistically significant (P < 0.05). Molecular Therapy 2005 12, 610-617DOI: (10.1016/j.ymthe.2005.06.094) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 3 Episomal gene repair assay. (A) Experimental setup. Repair and target plasmids are described in the text. The stop codons (bold, italics) and the recognition site for I-SceI (boxed) are highlighted. (B, C) Episomal gene repair. 293T cells transfected with repair plasmid (RP), target plasmid, and a nuclease expression vector were analyzed by flow cytometry after 2 days. The graph displays the fraction of EGFP-positive cells in relation to transfected cells. The presence or absence of RP is indicated by + or −, “cto” indicates control. In (B), cells were transfected with target plasmid “3-3” along with plasmids encoding different promoters and types of GZF3 nucleases. **Statistically significant (P < 0.01) stimulation of SDR; “nd” stands for “not determined” in the case in which the number of REx-positive cells was below 1% due to cell death. In (C), cells were transfected with “0-0”, “1-1”, “2-2”, “3-3”, or “4-4”, along with nuclease expression plasmids. **Statistically significant (P < 0.01) stimulation of HR comparing gene repair in the absence (“0-0”) and in the presence of respective binding sites (e.g., “1-1”). Molecular Therapy 2005 12, 610-617DOI: (10.1016/j.ymthe.2005.06.094) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 4 SDR stimulated by heterodimeric nucleases. (A) Episomal gene repair. 293T cells were transfected with “3-1” and plasmids coding for I-SceI, GZF1-N, and GZF3-N as indicated by +. **Statistically significant stimulation of gene repair (P < 0.001). (B) Chromosomal gene repair. 293/3-1 cells, which contain a single copy of target locus “3-1”, were transfected with repair plasmid (RP) and endonucleases as indicated by + (0.25 μg) and ‡ (0.75 μg). The columns designate the fraction of EGFP-positive cells 7 days posttransfection normalized for transfection efficiency. The presence or absence of RP is indicated by + or −. **Statistically significant stimulation (P < 0.01) of gene repair above basal HR. (C) Cytotoxicity. 293/3-1 cells were transfected with the same amounts of endonuclease expression vectors as for (B). The percentage of dead 293/3-1 cells was determined after 48 h by analyzing PI incorporation. The number of PI-positive cells is shown as a fraction of transfected cells. Molecular Therapy 2005 12, 610-617DOI: (10.1016/j.ymthe.2005.06.094) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions